Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers, Exosomes & Liquid Biopsy Asia 2019

Tae Ryong Lee's Biography



Tae Ryong Lee, Chief Scientific Officer, Rosetta Exosome

Dr. Tae Ryong Lee is currently the CSO of Rosetta Exosome, Seoul, Korea. He got his Ph. D. in enzymology from the Department of Chemistry at State University of New York at Buffalo after obtaining B.S. and M.S. in organic chemistry from the Department of Chemistry at Seoul National University. Before he joined Rosetta Exosome, he worked as a senior vice president and the director of Bioscience Division and Basic Research & Innovation Division at AmorePacific R&D Unit since 2011. He has authored over 140 peer reviewed papers and 300 patents covering broad range of chemistry and biology including 4 and 27 extracellular vesicles-related papers and patents, respectively. He has also been a member of KSEV (Korean Society for Extracellular Vesicles) since 2009.

Tae Ryong Lee Image

Bacterial Extracellular Vesicles as Next-Generation Cancer Immunotherapy

Tuesday, 10 September 2019 at 11:45

Add to Calendar ▼2019-09-10 11:45:002019-09-10 12:45:00Europe/LondonBacterial Extracellular Vesicles as Next-Generation Cancer ImmunotherapyCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com

Coley’s toxin is a mixture of bacterial species developed as a treatment for cancer by Dr. William Coley in the late 19th century and there have been many attempts to develop modern versions of Coley's toxins since then. These attempts were not so successful until the recent development of ‘cancer immunotherapy’ especially due to the toxic side effects. Extracellular vesicles (EVs) are considered to represent the characteristics of their origin, so we assumed that bacterial EVs can be key components of Coley’s toxin with reduced side effects. Therefore, we investigated bacterial EVs as a therapeutic agent for treating cancer. Several different cancers were grafted subcutaneously to mice and these mice were treated with EVs obtained from several Gram-negative and Gram-positive bacterial species including toxicity-reduced EVs from the msbB-deleted or LTA-mutant bacterial strains. Treatments of all EVs significantly reduced the tumor volumes in all tested cancers. In vivo IVIS imaging analyses showed that EVs were highly enriched in tumor tissue rather than spreading out the other organs. Cytokine analyses have revealed that IL12p40, IFN-? and CXCL10 cytokines increased in blood and tumor tissue upon EVs treatment. These results suggest that bacterial EVs are promising immunotherapeutic agents to treat various cancers and these could bring a new insight in the development of novel cancer immunotherapy.


Add to Calendar ▼2019-09-09 00:00:002019-09-10 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com